Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ABCL
- Price
- 3.17
- Stock movement down
- -0.08 (-2.16%)
- Company name
- Abcellera Biologics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.09B
- Ent value
- 1.40B
- Price/Sales
- 30.76
- Price/Book
- 3.22
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 112.40%
- 1 year return (CAGR)
- 53.81%
- 3 year return (CAGR)
- -24.49%
- 5 year return (CAGR)
- -37.82%
- 10 year return (CAGR)
- -
Last updated: 2026-03-04
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ABCL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 30.76 |
| Price to Book | 3.22 |
| EV to Sales | 39.50 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 299.34M |
| EPS (TTM) | -0.49 |
| FCF per share (TTM) | -0.58 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 75.13M |
| Gross profit (TTM) | 75.13M |
| Operating income (TTM) | -217.10M |
| Net income (TTM) | -146.41M |
| EPS (TTM) | -0.49 |
| EPS (1y forward) | -0.77 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -288.98% |
| Profit margin (TTM) | -194.88% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 155.01M |
| Net receivables | 153.40M |
| Total current assets | 728.23M |
| Goodwill | 47.81M |
| Intangible assets | 38.38M |
| Property, plant and equipment | 0.00 |
| Total assets | 1.36B |
| Accounts payable | 25.23M |
| Short/Current long term debt | 143.22M |
| Total current liabilities | 64.31M |
| Total liabilities | 215.59M |
| Shareholder's equity | 1.14B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -131.29M |
| Capital expenditures (TTM) | 42.77M |
| Free cash flow (TTM) | -174.07M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -12.83% |
| Return on Assets | -10.79% |
| Return on Invested Capital | -12.76% |
| Cash Return on Invested Capital | -15.17% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.70 |
| Daily high | 3.76 |
| Daily low | 3.60 |
| Daily Volume | 3.16M |
| All-time high | 53.20 |
| 1y analyst estimate | 9.17 |
| Beta | 0.87 |
| EPS (TTM) | -0.49 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 24 Feb 2026 |
Downside potential
Loading...
Downside potential data
| ABCL | S&P500 | |
| Current price drop from All-time high | -94.04% | -1.82% |
| Highest price drop | -96.37% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -81.16% | -10.84% |
| Avg time to new high | 218 days | 12 days |
| Max time to new high | 1278 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.09B
Marketcap category
Small-cap
Description
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Employees
562
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page